News

GE Vernova Reports Mixed Q3 Results Amid Revenue Growth Surge

GE Vernova Reports Mixed Q3 Results Amid Revenue Growth Surge

GE Vernova Inc. Third Quarter Performance Overview

GE Vernova Inc. (NYSE: GEV) experienced a dip in its stock prices during premarket trading following the announcement of its mixed third-quarter performance. However, the company did report notable revenue growth, signaling a positive trend despite some setbacks on earnings.

Revenue and Orders Increase

In the latest quarterly report, GE Vernova revealed an 8% year-over-year revenue increase, totaling $8.913 billion, with an impressive 10% organic growth, surpassing analysts' expectations of $8.783 billion. CEO Scott Strazik expressed confidence in the company's performance, highlighting strong service demand and robust margin improvements within their Power and Electrification sectors.

Significant Growth in Orders

The company reported receiving orders totaling $9.4 billion, reflecting a 17% organic growth. This growth was bolstered by a remarkable 28% increase in services, with all segments of the company achieving noteworthy results and equipment orders in Power and Electrification showing robust activity.

Earnings Performance

Despite the revenue increase, the earnings report showed a loss per share of $0.35, a decrease from a $0.62 loss per share a year prior. This shortfall slightly missed the earnings consensus set at $0.32 per share. However, the net loss was reduced to $99 million, down from $185 million reported last year, indicating an overall narrowing of losses, which may respond to investor concerns positively.

Adjusted Earnings Metrics

The adjusted EBITDA margin made a modest expansion of 20 basis points, reaching 2.7%, but saw a decrease of 70 basis points on an organic basis to 2.6%. Adjusted EBITDA for the period came in at $243 million, marking an 18.5% increase year-over-year.

Segment Insights

Diving deeper into segment performance, Power revenue jumped to $4.206 billion, demonstrating an 8% increase compared to the prior year. Orders for the Power segment climbed to $5.202 billion or a 28% improvement, primarily fueled by growth in Gas Power equipment and services.

Challenges in Wind and Growth in Electrification

Conversely, the Wind segment reported flat revenue at $2.89 billion, with orders falling 19% year-over-year to $1.747 billion. These figures reflect challenges faced in gaining Onshore Wind equipment orders outside North America. On the other hand, the Electrification sector performed admirably, achieving a revenue of $1.928 billion—a remarkable 22% increase, driven largely by successful Grid Solutions and Power Conversion initiatives with orders rising by 17% to $2.51 billion.

Cash Flow and Financial Health

One of the most positive takeaways from the financial report was the cash flow situation. Cash from operating activities soared to $1.127 billion, dramatically increasing from merely $233 million used during the same period last year. The company reported a free cash flow of $968 million, showcasing significant improvement.

Healthy Cash Reserves

As of the end of the quarter, GE Vernova boasts a strong cash reserve of $7.4 billion, increasing from $5.8 billion in the second quarter of 2024. This bolstered cash position provides a solid foundation for the company to navigate future opportunities and challenges in the market.

Outlook for 2024

Looking ahead, GE Vernova has reaffirmed its guidance for 2024, projecting revenues to trend towards the upper end of the estimated $34 billion to $35 billion range. The company also anticipates free cash flow to come in closer to the upper end of the $1.3 billion to $1.7 billion range. These forecasts reflect continued confidence in the company’s growth trajectory despite some headwinds faced in specific segments.

Market Response

Following the release of the financial results, shares of GE Vernova traded down by 4.49%, hitting a premarket mark of $264.00 as investors digest the mixed earnings report and growth opportunities ahead.

Frequently Asked Questions

What were GE Vernova's revenue and earnings for Q3?

GE Vernova reported third-quarter revenue of $8.913 billion, with a loss per share of $0.35.

How did GE Vernova's orders perform this quarter?

The company secured orders totaling $9.4 billion, showing significant organic growth of 17%.

What are GE Vernova's cash flow figures for the quarter?

Cash from operating activities was $1.127 billion, with total free cash flow of $968 million.

What segments did GE Vernova experience growth in?

Power and Electrification saw strong growth, while Wind faced challenges with a decline in orders.

What is GE Vernova's guidance for 2024?

The company projects revenues of $34 billion to $35 billion and anticipates free cash flow between $1.3 billion and $1.7 billion.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Melrose Fire Station Reaches Steel Topping Milestone

Updated Category News Views 4

Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...

Continue Reading
Fuse Oncology Showcases New iRT Workflow at ASTRO

Updated Category News Views 4

Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...

Continue Reading
IASO's FUCASO Shows Robust Results in 2026 Study

Updated Category News Views 7

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Continue Reading
Accuray, Samsung Push Boundaries with Imaging Deal

Updated Category News Views 4

In a move that's got the healthcare industry buzzing, Accuray Incorporated (NASDAQ: ARAY) announced its partnership with Samsung NeuroLogica to supercharge the CyberKnife® System. This isn't just another collaboration; it's a strategic pivot to advance imaging capabilities, marrying Samsung's volumetric innovations with Accuray's established precision in robotic...

Continue Reading
DKS Facing Class Action Over Stock Slump Allegations

Updated Category News Views 3

A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...

Continue Reading
Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Updated Category News Views 6

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Continue Reading
AI Memory Growth Pushes Limits at GMIF2026 Summit

Updated Category News Views 4

The Memory and Storage Race in the AI Era The 5th GMIF2026 Innovation Summit wrapped up in Shenzhen, and boy, was it a heavyweight bout. You could practically feel the tension in the room as industry giants sparred over the future of memory and storage in AI. This wasn't just another trade show pow-wow; this was a strategic chess match over where AI infrastructure is...

Continue Reading
Salveo Home Care Faces Class Action Over Labor Violations

Updated Category News Views 5

Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...

Continue Reading
Quay Shines in 2026 Prescription Sunglasses Lineup

Updated Category News Views 5

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...

Continue Reading
Leo Cancer Care's Upright Radiotherapy Milestone

Updated Category News Views 4

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

Continue Reading

Top 5 Most Recently Viewed Articles

Vaccinex Unveils Efficacy Insights for Pepinemab in Alzheimer’s Study

Updated Category News Views 71

Vaccinex Provides Update on Pepinemab Study for Alzheimer’s Disease ROCHESTER, N.Y. — Vaccinex, Inc. (NASDAQ: VCNX), a forward-thinking biotechnology firm, is making significant strides in the treatment of Alzheimer's disease (AD) and cancer. The company is focused on a unique approach through the inhibition of Semaphorin 4D (SEMA4D). Recently, it was announced that...

Continue Reading
Legal Inquiry into Netflix, Inc. (NFLX) Attracts Investor Attention

Updated Category News Views 287

Understanding the Investigation into Netflix, Inc. Recently, the law firm Robbins Geller Rudman & Dowd LLP has initiated a formal investigation into Netflix, Inc. (NASDAQ: NFLX). This inquiry primarily focuses on potential violations of U.S. federal securities laws that may have occurred within the company. The Implications for Investors This investigation comes at a...

Continue Reading
Norway's Wealth Fund Expands Portfolio with London Investment

Updated Category News Views 221

Norway's Sovereign Wealth Fund Takes Bold Step in London Norway's sovereign wealth fund, expertly managed by Norges Bank Investment Management, has recently made headlines with its strategic acquisition of a 25% stake in a notable portfolio of office and retail properties located in London's prestigious Mayfair district. Significant Investment in a Prime Location This...

Continue Reading
Exagen Inc. Announces New Biomarkers and Financial Success

Updated Category News Views 291

Exagen Inc. Introduces Groundbreaking Biomarkers for Autoimmune Diseases Innovative testing aims to enhance patient diagnosis and care Exagen Inc. (Nasdaq: XGN), a pioneering company in autoimmune testing, has achieved a significant milestone by receiving conditional approval from the New York State Department of Health for its advanced assays to diagnose systemic lupus...

Continue Reading
Pacaso's Financial Growth in 2025: A Closer Look At Results

Updated Category News Views 1306

Pacaso Shows Promising First Half Financial Performance Pacaso, the innovative platform for co-owned luxury vacation homes, has recently shared its financial results for the first half of 2025, demonstrating strong stability and improved efficiency despite a challenging broader housing market. The company reported an impressive adjusted gross profit while managing to...

Continue Reading